2. Academic Validation
  3. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses

  • J Thromb Haemost. 2021 Jul;19(7):1687-1696. doi: 10.1111/jth.15323.
Marianne Kjalke 1,  Mads Kjelgaard-Hansen 1,  Søren Andersen 2,  Ida Hilden 1
Affiliations

Affiliations

  • 1 Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
  • 2 Global Development, Novo Nordisk A/S, Bagsvaerd, Denmark.
PMID: 33819375 DOI: 10.1111/jth.15323
Abstract

Background: The anti-tissue factor plasma inhibitor monoclonal antibody concizumab is under clinical investigation for subcutaneous prophylaxis of hemophilia A/B (HA/HB) with or without inhibitors. Breakthrough bleeds while on concizumab prophylaxis may be treated with bypassing agents (recombinant activated factor VIIa [rFVIIa] and activated prothrombin complex concentrate [APCC]), or with Factor VIII (FVIII) or factor IX (FIX).

Objectives: To evaluate the effect of combining concizumab with rFVIIa, APCC, rFVIII, and rFIX on Thrombin generation (TG) potential.

Methods: Pooled HA plasma was spiked in vitro with concizumab alone or together with rFVIIa, APCC, or rFVIII. rFVIIa, APCC, and rFVIII were added ex vivo to plasma from HA patients receiving concizumab prophylaxis. Pooled HB plasma was spiked with concizumab alone or together with rFIX. TG potential was measured after initiation with tissue factor.

Results: Concizumab increased Thrombin peak in a concentration-dependent manner. Adding rFVIIa, APCC, rFVIII, or rFIX caused a further increase in Thrombin peak. The effects of concizumab and rFVIIa, APCC, rFVIII, or rFIX were mainly additive, with no or up to maximally ~25% extra effect caused by drug--drug interaction. No strong synergistic effects were observed upon combining concizumab with rFVIIa, APCC, rFVIII, or rFIX. The Thrombin peak obtained with 0.5 IU/ml rFVIII or rFIX in the presence of concizumab was on occasion slightly higher, but mostly comparable to the Thrombin peak with 1 IU/ml rFVIII or rFIX in the absence of concizumab.

Conclusion: rFVIIa, APCC, rFVIII, and rFIX enhanced plasma TG potential in the presence of concizumab. Dose levels of concomitant use should be adjusted accordingly to balance potential safety concerns while maintaining the necessary hemostatic effect. Please see the video in the Supplementary Material for an animated summary of the data presented.

Keywords

FEIBA; hemophilia A; hemophilia B; recombinant factor VIII; recombinant factor VIIa.

Figures
Products